Tailoring treatment in metastatic renal cell carcinoma

Affiliations

¹ Department of Urology, University Hospitals Leuven, Leuven, Belgium. Eduard.roussel@uzleuven.be.
² Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.
³ Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Comment

Eduard Roussel et al. Nat Rev Urol. 2022 Aug.

. 2022 Aug;19(8):455-456.

doi: 10.1038/s41585-022-00615-z. Epub 2022 Jun 9.

¹ Department of Urology, University Hospitals Leuven, Leuven, Belgium. Eduard.roussel@uzleuven.be.
² Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.
³ Department of Urology, University Hospitals Leuven, Leuven, Belgium.

No abstract available

Comment on

Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, Maillet D, Gross-Goupil M, Tournigand C, Laguerre B, Barthélémy P, Coquan E, Gravis G, Houede N, Cancel M, Huillard O, Beuzeboc P, Fournier L, Méjean A, Cathelineau X, Doumerc N, Paparel P, Bernhard JC, de la Taille A, Bensalah K, Tricard T, Waeckel T, Pignot G, Braychenko E, Caruso S, Sun CM, Verkarre V, Lacroix G, Moreira M, Meylan M, Bougouïn A, Phan L, Thibault-Carpentier C, Zucman-Rossi J, Fridman WH, Sautès-Fridman C, Oudard S. Vano YA, et al. Lancet Oncol. 2022 May;23(5):612-624. doi: 10.1016/S1470-2045(22)00128-0. Epub 2022 Apr 4. Lancet Oncol. 2022. PMID: 35390339 Clinical Trial.

1. Demasure, S. et al. Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. Acta Oncol. 61, 22–29 (2022). - DOI
1. Escudier, B. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 706–720 (2019). - DOI
1. Vano, Y.-A. et al. Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(22)00128-0 (2022). - DOI - PubMed
1. Beuselinck, B. et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin. Cancer Res. 21, 1329–1339 (2015). - DOI
1. Verbiest, A. et al. Clear-cell renal cell carcinoma: molecular characterization of IMDC risk groups and sarcomatoid tumors. Clin. Genitourin. Cancer 17, e981–e994 (2019). - DOI